• Intracellular biologics drug delivery start-up Entrada launches with $59 million
• Entrada Therapeutics Nabs $59M for Drugs that Gain “Entry” to Cells
• Entrada emerges with $59M to fund the delivery of biologic therapies into the cell
• Entrada launches today, taking a $59M shot at some tough intracellular targets
• Boston biotech Entrada launches with $59M to tackle deadly disease
• Entrada Therapeutics launches with $59 million in VC funding
• ENTRADA RAISES $59M SERIES A TO TAKE INTRACELLULAR BIOLOGIC INTO CLINIC
• A Trio of Companies Launch Today to Target Cancer, Mitochondria, and Hearing Loss